In a landmark shift for reproductive healthcare in the United States, newly published research from the University of Southern California reveals that following the Food and Drug Administration’s removal of in-person dispensing requirements for mifepristone, accessibility to this critical abortion medication at traditional retail pharmacies remains conspicuously restricted. Despite regulatory changes intended to enhance patient access nationwide, a comprehensive study appearing in JAMA highlights that retail pharmacies contribute only a small fraction of mifepristone dispenses, with mail-order pharmacies overwhelmingly dominating post-policy distributions.
Mifepristone, a cornerstone drug in medication abortion regimens, was historically subject to stringent FDA Risk Evaluation and Mitigation Strategies (REMS) that mandated patients physically obtain the medication from clinics or hospitals. This requirement often acted as a barrier, particularly for individuals in medically underserved or rural areas. In January 2023, the FDA removed this in-person dispensing rule, allowing certified providers to prescribe mifepristone with the option for fulfillment at pharmacies or via mail-order services, theoretically broadening therapeutic reach and convenience exponentially.
However, the USC-led analysis demonstrates a nuanced reality: approximately 2,700 mifepristone prescriptions per month are now filled nationwide, yet mail-order pharmacies in states with legal abortion access and telehealth permissions dispense nearly all these medications. Brick-and-mortar outlets account for less than two percent of dispensing activity even in these abortion-friendly environments, underscoring the enduring physical access barriers despite regulatory liberalization. The limited retail pharmacy fills predominantly occur in independent pharmacies rather than national or regional chains, suggesting potential reluctance within large pharmacy corporations to fully embrace dispensing responsibilities.
Christopher Scannell, the study’s first author, emphasized the critical role that mail-order pharmacy channels have played post-Dobbs Supreme Court ruling and post-REMS change. The rapid uptick in medication abortion distribution after policy revision validates telehealth and remote dispensing as effective modalities for expanding access. Nonetheless, the data further illuminate disparities, as individuals requiring immediate access, lacking stable internet connectivity, or desiring direct pharmacist counseling for medication support may still face significant hurdles when restricted to mail distribution.
Lead author Dima M. Qato pointed to concerning systemic shortcomings within retail pharmacy integration, even in states supporting both abortion rights and telehealth. This mismatch suggests intrinsic barriers—whether regulatory, corporate, or socio-political—inhibiting comprehensive adoption of mifepristone dispensing in physical pharmacy settings. Overcoming such barriers is essential to fully realize equitable medication abortion access, especially when the convenience and privacy of telehealth are not feasible for all patient populations.
Pharmacy chains have publicly navigated a controversial landscape following the FDA’s deregulatory announcement. While prominent chains such as CVS and Walgreens have selectively introduced mifepristone availability at certain locations in permissive states, others like Costco have openly declined to stock the medication, and many remain noncommittal. This ambivalence among large retail chains signifies the complex interplay of public advocacy, political pressure, and corporate strategy shaping abortion care delivery within the pharmaceutical sector.
Interestingly, in states where abortion remains legal but telehealth prescribing faces restrictions, retail pharmacies constitute a substantial share—around 61%—of mifepristone dispensing. This contrast highlights the indispensable role physical pharmacies continue to play where medication abortion access depends more heavily on immediate, in-person fills rather than remote delivery. It underscores the heterogeneity of regulatory environments shaping how patients obtain abortion medication across the country.
The policy modification has also subtly shifted the clinical landscape of medication abortion provision. While obstetricians and gynecologists have traditionally predominated in in-clinic abortion care, the easing of dispensing protocols appears to empower a broader cadre of healthcare providers—including primary care physicians and advanced practice clinicians such as nurse practitioners—to facilitate medication abortion remotely. This diversification may enhance patient reach, especially in areas with limited specialist availability, yet it further emphasizes the reliance on telehealth and mail-order pharmacy infrastructure.
The study’s methodology involved a rigorous two-year comparison spanning intervals before and after the FDA policy revision. It incorporated examination of dispensed prescription data tied to individuals’ reported state of residence, though the authors note the possibility of geographical misreporting by patients seeking medication abortion across state lines. Future research directions suggested include evaluation of shield laws designed to protect patient privacy and facilitate cross-jurisdictional access, particularly in states with restrictive abortion laws.
This USC investigation offers critical insights into how regulatory reform interacts with existing healthcare delivery networks and social determinants to shape real-world medication abortion access in the evolving post-Dobbs regulatory milieu. The findings reveal that despite policy progress intended to democratize availability, entrenched infrastructural and sociopolitical barriers continue to constrain equitable distribution. Addressing these gaps is vital for public health stakeholders aiming to ensure that life-saving reproductive healthcare is genuinely accessible to all who need it.
The implications of this research extend beyond mifepristone alone, reflecting broader challenges in implementing medication access reforms amidst a politically charged environment. They underscore the importance of nuanced policy frameworks that consider diverse patient needs, provider profiles, and market behaviors. As the landscape of abortion care delivery continues to adapt, coordinated efforts among regulatory bodies, healthcare systems, pharmacy sectors, and advocacy organizations remain essential to translating regulatory intent into meaningful patient outcomes.
As mail-order pharmacies remain the predominant channel for mifepristone post-REMS, this trend underlines the potential of telehealth innovation but simultaneously signals the necessity of reinforcing physical pharmacy availability to build a comprehensive, hybrid model of medication abortion provision. This balanced approach could mitigate disparities rooted in geographic, socioeconomic, and technological divides—ensuring that all individuals have timely, dignified access to reproductive healthcare options.
The USC Schaeffer Institute’s team, in collaboration with researchers Pragya Kakani and Rebecca Myerson, has paved the way for critical ongoing dialogues regarding both the successes and limitations inherent in current medication abortion dispensing frameworks. Their findings invite stakeholders to critically evaluate how policy, provider practices, and pharmacy capacities intersect—and where targeted interventions are most urgently needed to dismantle lingering access barriers.
Subject of Research: Medication Abortion Access and Mifepristone Dispensing Policies
Article Title: Limited Use of Retail Pharmacy Dispensing for Mifepristone Following FDA In-Person Requirement Removal
News Publication Date: 13-Apr-2026
Web References: http://dx.doi.org/10.1001/jama.2026.3419
Image Credits: USC Schaeffer Institute
Keywords: Abortion, Mifepristone, Medication Abortion, FDA REMS, Telehealth, Pharmacy Dispensing, Reproductive Health Access, Health Policy, Medication Delivery Systems
